Box office
Moviesfera Newsroom
Box office

Clayface's modest opening is a verdict on superhero IP, not only DC

An estimated $24 million R-rated opening says the DC badge no longer sells tickets alone. Warner's real win here is a $44 million budget, not any revival of superhero hype.

Published
October 25, 2026
Reading time
4 min
Categories
Box office

AI-generated image

What is a DC logo worth in 2026? Judging by this weekend, not much more than a good horror hook. Clayface topped the box office with an estimated $24 million domestic opening, and Warner Bros. will gladly take the trophy. But the number underneath it deserves a harder look.

The studio had projected an opening of $25 million to $30 million domestically, according to The Hollywood Reporter, which also noted the film's $44 million budget and a $20 million to $25 million international projection. If the $24 million estimate holds, it lands slightly under that forecast. It is also the first DC Studios release since Supergirl ran into box office headwinds over the summer.

The brand isn't doing the selling anymore

Here is our reading: when an R-rated horror film sold under the DC Comics banner opens at or below its own studio's projection, that is at least a partial verdict on the IP. Horror is the genre whose grip on the box office, as NPR puts it, "shows no sign of weakening," and we think Clayface is riding that current more than any affection for the DCU.

Look at the previews. Screen Rant notes that its $3.5 million Thursday haul was less than half of Supergirl's. The same piece points out that Supergirl was PG-13 and opened in summer, so the comparison isn't clean. Fair. But Clayface also trails the previews of the R-rated Birds of Prey and The Suicide Squad. The caveats don't change the larger picture: an oddball villain movie with no Batman in it was never going to open like an event.

There is an uncomfortable irony too. NPR's review argues the film plants "one of its feet of clay in horror and the other in superhero," and that it is too quick to retract its feelers when it meets resistance. If the product hedges between two audiences, the poster can't promise either one cleanly. In our view, a Batman-free "DC" label may even be a small tax rather than a bonus.

The real winner is the spreadsheet

Here is where the story turns. Clayface carries a reported $44 million budget. Supergirl cost at least $170 million and grossed $126.4 million; Superman cost a reported $225 million and made $618.7 million. Against those, Clayface is a rounding error with a pulse.

Screen Rant estimates a break-even of around $110 million and a possible final gross of $85 million to $120 million. That is a projection, not a result, and the margin is thin. Still, a movie that can plausibly limp to profit has a very different risk profile from a $170 million gamble that needs the brand to carry it.

We'd argue this is the genuine lesson for Warner: not "superheroes are back," but "superheroes are survivable when they're cheap." Strong reviews help as well. Screen Rant cites a 75% critics' score and a 94% audience score, against Supergirl's 52% and 72%. Good word of mouth is the one thing a modest opening can still buy.

What Warner should take from it

Clayface looks like a sensible template: a mid-budget genre film, a director in James Watkins whom Variety's Guy Lodge calls a "reliable British genre craftsman," a script credited to Mike Flanagan and Hossein Amini, and a price tag that lets the film be wrong without being a disaster. NPR calls it "a test case" for whether the DC Universe can stretch toward something more lucrative than the superhero genre. We'd say the early answer is "yes, but only if it stays small."

What would be a mistake is reading $24 million as proof that audiences want a gorier DCU. They showed up in decent but unspectacular numbers, and a lot of that may simply be horror season. The same weekend, A24's Elizabeth Holmes documentary You Can See Everything, which opened to $15 million, reportedly rose another 28% in its second weekend while expanding to more theaters. A documentary about Theranos running in the same neighborhood as a studio comic-book movie is not a sentence that flatters the genre's pull.

Our verdict: celebrate the discipline, not the hype. If the DCU wants to prove the brand still matters, it will have to do it with the next big-budget swing, not with the cheapest of its three films so far. Until then, Clayface is a good-value horror movie that happens to wear a famous logo, and that may be the healthiest thing that could have happened to it.

Debate topics

No topics yet: start the first one.

More stories